A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants

NCT03437083 · clinicaltrials.gov ↗

COMPLETED

Status

340

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Breast Cancer

Interventions

DRUG: Eribulin mesylate

Sponsor

Eisai Korea Inc.